We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Vedanta Granted U.S. Patent
News

Vedanta Granted U.S. Patent

Vedanta Granted U.S. Patent
News

Vedanta Granted U.S. Patent

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Vedanta Granted U.S. Patent"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Vedanta Biosciences has announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,415,079. The patent broadly covers pharmaceutical compositions and mixtures of Clostridium live bacterial strains and builds on Vedanta’s patent issuances in Japan. The issued patent is exclusively licensed worldwide to Vedanta under an agreement with the University of Tokyo and provides coverage through at least 2031.

The patented technology is based on ground-breaking work by Dr. Kenya Honda, a scientific co-founder of Vedanta. Dr. Honda’s work provides an avenue for the treatment of a variety of diseases including immune and infectious diseases employing bacterial strains belonging to Clostridium clusters IV and/or XIVa. Clostridium bacteria include a variety of spore-forming species that can abundantly colonize the gut. 

“We believe this issuance puts Vedanta in an IP leadership position in the microbiome field,” said Bernat Olle, Ph.D., Chief Executive Officer of Vedanta. “The patent has broad, fundamental claims that we believe will be important for the commercialization of microbiome therapeutics based on bacterial consortia. We intend to continue to build value from our IP estate through our internal programs as well as alliances with pharmaceutical partners.” 

Advertisement